Two landmark papers by Rob Bristow and team

 

Congratulations to Dr. Rob Bristow on two landmark papers on prostate cancer which have been accepted into Nature and Nature Communications respectively.

The first paper - "Epigenomic and Genomic Correlates of Aggression in Curable Prostate Cancer", with Rob as Senior Co-author with Paul Boutros (OICR), and lead author Mike Fraser (Scientific Associate Director of the Precision Radiation Medicine Research Program), describes a prognostic signature based on integrating mutation, copy number alteration (CNA), and methylation status of tumour tissues.

The second paper “Germline BRCA2 Mutations Drive Prostate Cancers with Distinct Evolutionary Trajectories”, again with Rob & Paul as Senior Co-authors, describes the genetic basis as to why men with germline mutations of BRCA2 develop such aggressive localized cancers (50% dead at 5 years).

UTDRO Chair, Dr. Fei-Fei Liu congratulated the teams involved: "This is a clear demonstration of excellence of team science at its best! Congratulations to Rob on his outstanding scientific leadership, and invaluable contributions to clinical and biological insights for men with prostate cancer."